Valuation: Rapport Therapeutics, Inc.

Market Cap 1.6B 1.41B 1.33B 1.21B 2.27B 154B 2.29B 15.98B 6.17B 78.59B 6.02B 5.89B 253B P/E 2026 *
-8.26x
P/E 2027 * -6.82x
Enterprise Value 1.28B 1.12B 1.06B 962M 1.81B 122B 1.82B 12.7B 4.9B 62.47B 4.79B 4.68B 201B EV / Sales 2026 *
63.8x
EV / Sales 2027 * -
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rapport Therapeutics, Inc.

1 day-1.39%
1 week-15.68%
Current month-31.29%
1 month-31.43%
3 months-16.53%
6 months+20.11%
Current year+10.22%
1 week 31.58
Extreme 31.58
41.47
1 month 31.58
Extreme 31.58
50.34
Current year 25.21
Extreme 25.21
52.93
1 year 23.75
Extreme 23.75
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 01/01/2023
Chief Executive Officer 48 01/02/2023
Director of Finance/CFO 58 01/11/2023
Director TitleAgeSince
Director/Board Member 61 23/08/2023
Director/Board Member 48 01/03/2023
Director/Board Member 54 01/02/2022
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Sell

Chief Executive Officer

-2,210 0.0046%
08/09/26 Sell

Chief Executive Officer

-8,210 0.0171%
25/08/26 Sell

Executive/Senior Manager

-37,000 0.0774%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-15.68%+25.76% - 1.6B
+2.64%+6.45%+11.87%+38.40% 49.06B
+0.22%+0.40%+50.91%+37.06% 44.6B
-1.58%+4.66%+359.34%+614.38% 43.24B
+1.70%+0.36%+12.56%+99.27% 41.73B
+0.51%-1.71%+5.18%+46.87% 29.93B
-0.48%-1.32%+23.98%+150.01% 17.19B
+0.08%+9.03%+8.41% - 15.35B
+1.76%+0.85%+29.13%+48.42% 15.54B
+1.97%-3.17% - - 15.11B
Average +0.54%+0.10%+58.57%+147.77% 27.34B
Weighted average by Cap. +0.75%+2.15%+77.85%+161.54%

Financials

2026 *2027 *
Net sales 20M 17.59M 16.63M 15.09M 28.33M 1.92B 28.5M 199M 76.92M 980M 75.09M 73.46M 3.15B -
Net income -194M -171M -161M -146M -275M -18.63B -277M -1.93B -747M -9.51B -729M -713M -30.56B -252M -222M -210M -190M -358M -24.23B -360M -2.51B -971M -12.36B -948M -927M -39.73B
Net Debt -329M -289M -274M -248M -466M -31.59B -469M -3.28B -1.27B -16.12B -1.24B -1.21B -51.8B -477M -419M -396M -360M -675M -45.76B -679M -4.75B -1.83B -23.35B -1.79B -1.75B -75.03B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
28/09/26 $33.44 -1.39% 552,306
25/09/26 $33.91 +0.24% 711,808
24/09/26 $33.83 -0.88% 848,741
23/09/26 $34.13 -17.70% 745,549
22/09/26 $41.47 +4.56% 900,214
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
33.44USD
Average target price
62.88USD
Spread / Average Target
+88.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock